Mad for mAbs and Oral Outpatient COVID-19 Treatments

<p>Cassandra J. Schmitt, PharmD, determines risk factors associated with severe COVID-19 disease progression, discusses efficacy and safety outcomes of novel agents for the outpatient treatment of COVID-19, identifies the ideal candidate to receive treatment with oral molnupiravir, nirmatrelvir/ritonavir, or intravenous monoclonal antibodies for mild-to-moderate COVID-19.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>